AxoGen, Inc. to Report Fourth Quarter and 2016 Full Year Financial Results and Host Conference Call on Wednesday, February 2...
February 08 2017 - 7:00AM
AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced that it will report fourth quarter and
2016 full year financial results on Wednesday, February 22, 2017
after the market closes. AxoGen management will host an
investment-community conference call and web cast following the
release at 4:30 p.m. ET to discuss the financial results and
provide a corporate update.
Investors interested in participating in the conference call by
phone may do so by dialing toll free at (877) 407-0993, or use the
direct dial-in number at (201) 689-8795. Those interested in
listening to the conference call live via the Internet may do so by
visiting http://axogeninc.equisolvewebcast.com/q3-2016.
Following the conference call, a replay will be available in the
Investors section of the company's website at
www.axogeninc.com.
About AxoGen, Inc. AxoGen (AXGN) is a global
leader in innovative surgical solutions for peripheral nerve
injuries. AxoGen's portfolio of products includes Avance® Nerve
Graft, an off-the-shelf processed human nerve allograft for
bridging severed nerves without the comorbidities associated with a
second surgical site, AxoGuard® Nerve Connector, a porcine
submucosa extracellular matrix (ECM) coaptation aid for tensionless
repair of severed nerves, AxoGuard® Nerve Protector, a porcine
submucosa ECM product used to wrap and protect injured peripheral
nerves and reinforce the nerve reconstruction while preventing soft
tissue attachments, and Avive™ Soft Tissue Membrane, a
minimally processed human umbilical cord membrane that may be used
as a soft tissue covering to reduce inflammation and scar tissue
formation. Along with these core surgical products, AxoGen also
offers AxoTouch™ Two-Point Discriminator and AcroVal™ Neurosensory
& Motor Testing System. These evaluation and measurement tools
assist health care professionals in detecting changes in sensation,
assessing return of sensory, grip, and pinch function, evaluating
effective treatment interventions, and providing feedback to
patients on nerve function. The AxoGen portfolio of products is
available in the United States, Canada, the United Kingdom, and
several European and international countries.
Cautionary Statements Concerning Forward-Looking
Statements This Press Release contains "forward-looking"
statements as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current
expectations or predictions of future conditions, events, or
results based on various assumptions and management's estimates of
trends and economic factors in the markets in which we are active,
as well as our business plans. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks,"
"estimates," "projects," "forecasts," "continue," "may," "should,"
"will," and variations of such words and similar expressions are
intended to identify such forward-looking statements. The
forward-looking statements may include, without limitation,
statements regarding our growth, our 2017 guidance, product
development, product potential, financial performance, sales
growth, product adoption, market awareness of our products, data
validation, our visibility at and sponsorship of conferences and
educational events. The forward-looking statements are subject to
risks and uncertainties, which may cause results to differ
materially from those set forth in the statements. Forward-looking
statements in this release should be evaluated together with the
many uncertainties that affect AxoGen's business and its market,
particularly those discussed in the risk factors and cautionary
statements in AxoGen's filings with the Securities and Exchange
Commission. Forward-looking statements are not guarantees of future
performance, and actual results may differ materially from those
projected. The forward-looking statements are representative only
as of the date they are made and, except as required by law, AxoGen
assumes no responsibility to update any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
InvestorRelations@AxoGenInc.com
The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2023 to Sep 2024